Display options
Cite
Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012;3:96doi: 10.3389/fphar.2012.00096.
Politis, M., Su, P., & Piccini, P. (2012). Imaging of microglia in patients with neurodegenerative disorders. Frontiers in pharmacology, 396. https://doi.org/10.3389/fphar.2012.00096
Politis, Marios, et al. "Imaging of microglia in patients with neurodegenerative disorders." Frontiers in pharmacology vol. 3 (2012): 96. doi: https://doi.org/10.3389/fphar.2012.00096
Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012 May 29;3:96. doi: 10.3389/fphar.2012.00096. eCollection 2012. PMID: 22661951; PMCID: PMC3361961.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2012 May 29;3:96. doi: 10.3389/fphar.2012.00096. eCollection 2012.

Imaging of microglia in patients with neurodegenerative disorders.

Frontiers in pharmacology

Marios Politis, Paul Su, Paola Piccini

Affiliations

  1. Division of Experimental Medicine, Faculty of Medicine, Centre for Neuroscience, Hammersmith Hospital, Imperial College London London, UK.

PMID: 22661951 PMCID: PMC3361961 DOI: 10.3389/fphar.2012.00096

Abstract

Microglia constitute the main immune defense in the central nervous system. In response to neuronal injury, microglia become activated, acquire phagocytic properties, and release a wide range of pro-inflammatory mediators that are essential for the annihilation of the neuronal insult. Although the role of microglial activation in acute neuronal damage is well defined, the pathophysiological processes underlying destructive or protective role to neurons following chronic exposure to microglial activation is still a subject of debate. It is likely that chronic exposure induces detrimental effects by promoting neuronal death through the release of neurotoxic factors. Positron emission tomography (PET) imaging with the use of translocator protein (TSPO) radioligands provides an in vivo tool for tracking the progression and severity of neuroinflammation in neurodegenerative disease. TSPO expression is correlated to the extent of microglial activation and the measurement of TSPO uptake in vivo with PET is a useful indicator of active disease. Although understanding of the interaction between radioligands and TSPO is not completely clear, there is a wide interest in application of TSPO imaging in neurodegenerative disease. In this article, we aim to review the applications of in vivo microglia imaging in neurodegenerative disorders such as Parkinson's disease, Huntington's disease, Dementias, and Multiple Sclerosis.

Keywords: Huntington; PET; PK11195; Parkinson; dementia; microglia; multiple sclerosis

References

  1. J Cereb Blood Flow Metab. 2007 Jan;27(1):173-84 - PubMed
  2. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2304-19 - PubMed
  3. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):129-33 - PubMed
  4. Neuroscience. 2009 Feb 6;158(3):1030-8 - PubMed
  5. Ann Neurol. 2003;54 Suppl 5:S24-8 - PubMed
  6. PLoS One. 2010 Jan 20;5(1):e8784 - PubMed
  7. Neurosci Lett. 1998 Jan 23;241(1):53-6 - PubMed
  8. Mov Disord. 2007 Nov 15;22(15):2196-203 - PubMed
  9. J Neuropathol Exp Neurol. 2004 Jan;63(1):43-52 - PubMed
  10. Neurology. 2006 Nov 28;67(10):1880-3 - PubMed
  11. Neurobiol Dis. 2008 Dec;32(3):412-9 - PubMed
  12. Parkinsonism Relat Disord. 2010 Jan;16(1):57-9 - PubMed
  13. Ann Neurol. 2001 Sep;50(3):389-400 - PubMed
  14. Ann Neurol. 1988 Dec;24(6):708-12 - PubMed
  15. Acta Neurol Scand. 2002 Dec;106(6):325-32 - PubMed
  16. Brain. 2000 Nov;123 ( Pt 11):2321-37 - PubMed
  17. J Neuropathol Exp Neurol. 2002 Nov;61(11):1013-21 - PubMed
  18. J Neurosci. 2005 Sep 7;25(36):8240-9 - PubMed
  19. Neurology. 2009 Jan 6;72(1):56-62 - PubMed
  20. Rev Prat. 2006 Jun 30;56(12):1293-8 - PubMed
  21. Neurobiol Dis. 2010 Mar;37(3):630-40 - PubMed
  22. Neurosci Lett. 1993 Oct 14;161(1):89-92 - PubMed
  23. Glia. 2007 Nov 1;55(14):1459-68 - PubMed
  24. Am J Pathol. 1998 Jan;152(1):307-17 - PubMed
  25. Neuropathol Appl Neurobiol. 2009 Jun;35(3):306-28 - PubMed
  26. Ann Neurol. 2005 Feb;57(2):168-75 - PubMed
  27. Neurosci Lett. 1994 Jan 3;165(1-2):208-10 - PubMed
  28. Pharmacol Ther. 2008 Apr;118(1):1-17 - PubMed
  29. Trends Pharmacol Sci. 2006 Aug;27(8):402-9 - PubMed
  30. Neuroscience. 1998 Feb;82(3):805-17 - PubMed
  31. J Endocrinol. 2009 Sep;202(3):431-9 - PubMed
  32. Ann Neurol. 2010 Oct;68(4):477-93 - PubMed
  33. Trends Neurosci. 1996 Aug;19(8):312-8 - PubMed
  34. Schweiz Med Wochenschr. 1990 Jul 28;120(30):1083-90 - PubMed
  35. Brain. 2002 Jul;125(Pt 7):1462-73 - PubMed
  36. J Neuroimmunol. 2009 May 29;210(1-2):3-12 - PubMed
  37. Mov Disord. 2004 Jul;19(7):817-821 - PubMed
  38. Annu Rev Immunol. 2009;27:119-45 - PubMed
  39. Neurology. 1994 Nov;44(11):2015-9 - PubMed
  40. Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):63-7 - PubMed
  41. J Cereb Blood Flow Metab. 2010 Sep;30(9):1608-18 - PubMed
  42. J Neurol Sci. 2008 Nov 15;274(1-2):45-7 - PubMed
  43. Neurology. 2003 Sep 9;61(5):686-9 - PubMed
  44. Lancet. 2008 Oct 25;372(9648):1502-17 - PubMed
  45. Science. 2002 Jul 19;297(5580):353-6 - PubMed
  46. N Engl J Med. 2000 Nov 16;343(20):1430-8 - PubMed
  47. Brain. 2007 Nov;130(Pt 11):2816-29 - PubMed
  48. J Neuropathol Exp Neurol. 2001 Feb;60(2):161-72 - PubMed
  49. Nat Med. 2005 Feb;11(2):146-52 - PubMed
  50. Ann Neurol. 2004 Apr;55(4):458-68 - PubMed
  51. J Neuropathol Exp Neurol. 2000 Jun;59(6):513-24 - PubMed
  52. J Neurosci. 2008 Apr 16;28(16):4283-92 - PubMed
  53. Neurology. 1998 Dec;51(6):1546-54 - PubMed
  54. Ann Neurol. 1999 Oct;46(4):598-605 - PubMed
  55. Mult Scler. 2005 Apr;11(2):127-34 - PubMed
  56. Neuroscience. 1990;39(1):151-70 - PubMed
  57. Hum Brain Mapp. 2011 Feb;32(2):258-70 - PubMed
  58. Antioxid Redox Signal. 2009 Sep;11(9):2151-66 - PubMed
  59. Ann Neurol. 2008 Feb;63(2):174-83 - PubMed
  60. Lancet. 2001 Aug 11;358(9280):461-7 - PubMed
  61. Neurology. 2012 Aug 7;79(6):523-30 - PubMed
  62. Brain. 2001 Aug;124(Pt 8):1635-45 - PubMed
  63. Ann Neurol. 2004 Dec;56(6):894-7 - PubMed
  64. J Neurosci Res. 1997 Oct 15;50(2):345-53 - PubMed
  65. Brain. 2007 Jul;130(Pt 7):1759-66 - PubMed
  66. J Neurochem. 2002 Nov;83(3):546-55 - PubMed
  67. Exp Neurol. 2000 Jun;163(2):348-56 - PubMed
  68. Neurology. 2006 Jun 13;66(11):1638-43 - PubMed
  69. Exp Neurol. 1999 Oct;159(2):362-76 - PubMed
  70. Biol Psychiatry. 2008 Nov 15;64(10):835-41 - PubMed
  71. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S47-53 - PubMed
  72. Neuropathology. 2003 Dec;23(4):318-26 - PubMed
  73. Brain Res. 1996 Mar 25;713(1-2):192-8 - PubMed
  74. Neurobiol Dis. 2006 Oct;24(1):183-93 - PubMed
  75. Mov Disord. 2004 Oct;19(10):1221-6 - PubMed
  76. Eur J Neurol. 2011 Feb;18(2):226-231 - PubMed
  77. J Mol Med (Berl). 1997 Mar;75(3):165-73 - PubMed
  78. Neuroimage. 2008 Mar 1;40(1):43-52 - PubMed
  79. Glia. 2002 Nov;40(2):232-9 - PubMed
  80. Acta Neuropathol. 1998 Apr;95(4):338-44 - PubMed
  81. Acta Neuropathol. 2003 Dec;106(6):518-26 - PubMed
  82. Neurology. 1999 Dec 10;53(9):2199-203 - PubMed
  83. J Nucl Med. 2006 Jan;47(1):43-50 - PubMed
  84. Brain. 2005 Nov;128(Pt 11):2705-12 - PubMed
  85. Neurology. 1988 Aug;38(8):1285-91 - PubMed
  86. Neurobiol Aging. 2011 Mar;32(3):387-97 - PubMed
  87. Am J Pathol. 2001 Jan;158(1):63-73 - PubMed
  88. Eur J Pharmacol. 1991 Aug 6;200(2-3):347-51 - PubMed
  89. Acta Neuropathol. 1992;83(3):328-32 - PubMed
  90. Arch Neurol. 1968 Jan;18(1):20-33 - PubMed
  91. Nucl Med Biol. 1993 May;20(4):503-25 - PubMed
  92. J Neurol Sci. 2008 Jan 15;264(1-2):9-17 - PubMed
  93. Eur J Neurol. 2003 May;10(3):257-64 - PubMed
  94. Brain. 1989 Oct;112 ( Pt 5):1171-92 - PubMed
  95. Brain. 2008 Nov;131(Pt 11):2860-9 - PubMed
  96. Glia. 2002 Nov;40(2):206-17 - PubMed
  97. J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46 - PubMed
  98. J Neurosci. 2005 Mar 9;25(10):2566-75 - PubMed
  99. J Med Chem. 2009 Feb 12;52(3):581-92 - PubMed
  100. J Neuropathol Exp Neurol. 2001 Jun;60(6):647-57 - PubMed
  101. Am J Pathol. 1999 Jun;154(6):1673-84 - PubMed
  102. Curr Med Chem. 2007;14(11):1189-97 - PubMed
  103. J Proteome Res. 2007 Jul;6(7):2833-40 - PubMed
  104. J Neuroimmunol. 2005 Jan;158(1-2):58-66 - PubMed
  105. Mov Disord. 2006 Jan;21(1):89-93 - PubMed
  106. J Neurosci. 1995 Jul;15(7 Pt 2):5263-74 - PubMed
  107. Neurodegeneration. 1996 Jun;5(2):137-43 - PubMed
  108. Neurobiol Aging. 2009 Aug;30(8):1217-26 - PubMed
  109. J Neuropathol Exp Neurol. 1998 May;57(5):369-84 - PubMed
  110. J Exp Med. 2008 Aug 4;205(8):1869-77 - PubMed
  111. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):343-51 - PubMed
  112. Neuroreport. 1998 Sep 14;9(13):3029-32 - PubMed
  113. Brain. 2002 Jan;125(Pt 1):75-85 - PubMed
  114. Brain Res. 2007 Jul 23;1159:8-17 - PubMed
  115. Arch Neurol. 2009 Jan;66(1):60-7 - PubMed
  116. Glia. 2006 Sep;54(4):297-303 - PubMed
  117. Neurobiol Dis. 2003 Dec;14(3):417-24 - PubMed
  118. FASEB J. 2005 Apr;19(6):533-42 - PubMed
  119. J Neurol Sci. 2006 Oct 25;248(1-2):255-8 - PubMed
  120. Acta Neuropathol. 1988;76(6):550-7 - PubMed
  121. J Neuroimmune Pharmacol. 2011 Sep;6(3):354-61 - PubMed
  122. Neurobiol Dis. 2006 Feb;21(2):404-12 - PubMed
  123. Neurobiol Aging. 2001 Nov-Dec;22(6):1007-12 - PubMed
  124. J Neurosci Res. 1999 Aug 1;57(3):388-98 - PubMed
  125. Neurology. 2009 Sep 8;73(10):754-60 - PubMed

Publication Types

Grant support